相关实验视频

Updated: May 9, 2025

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

血管新生与子宫癌之间的相互作用:综合性综述

Addrita Nandi¹, Arabinda Ghosh², Samir Kumar Sil¹

¹Molecular Genetics and Cancer Biology Laboratory, Department of Human Physiology, Tripura University, Suryamaninagar, Tripura (West), India.

Expert review of anticancer therapy

|May 5, 2025

概括

宫癌血管生成是一个关键的治疗点. 本综述探讨了分子途径,抗血管生成药物和生物标志物,强调了需要可访问的治疗方法的需要.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

宫癌仍然是一个重大的全球卫生挑战,特别是在资源有限的地区.
瘤血管生成对于宫癌的进展,转移和治疗耐药性至关重要.
向血管生成为宫癌提供了一个有希望的治疗途径.

研究的目的:

审查驱动宫癌血管生成的关键分子机制.
讨论目前和新兴的宫癌抗血管性疗法.
突出生物标志物的作用,并解决治疗可访问性方面的挑战.

主要方法:

在PubMed,Scopus和Google Scholar的综合文献搜索到2025年3月.
专注于宫癌中的VEGF/VEGFR信号传导,HIF-1α和PI3K/Akt通路.
对抗血管性疗法的审查,包括贝瓦齐祖马布,小分子和纳米粒子输送.

主要成果:

像VEGF/VEGFR,HIF-1α和PI3K/Akt这样的关键分子通路是宫癌血管生成的核心.
抗血管生成疗法看起来很有前途,但面临的挑战是耐药性,毒性和成本.
与血管生成相关的生物标志物对于诊断和治疗选择至关重要.

结论:

组合疗法 (免疫疗法,化疗,向药物) 可能会提高疗效.
精准医疗方法利用多omics和AI具有改善结果的潜力.
需要进一步的研究来开发协同作用的药物组合,并普及宫癌的创新治疗方法.

关键词:

血管新生的产生.抗血管性药物抗血管性药物宫癌是发生在宫癌的原因之一.在VEGF中,VEGF是VEGF.在VEGFR中,VEGFR是VEGFR.

更多相关视频

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

相关概念视频

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Overview of Cell-Matrix Interactions

Overview of Cell-Matrix Interactions

The extracellular matrix or ECM holds cells together to form a tissue and allows the cells within the tissue to communicate. ECM comprises proteins such as fibronectin, collagen, laminin, etc. The most abundant protein in this space is collagen. Collagen fibers are interwoven with carbohydrate-containing protein molecules called proteoglycans. ECM allows cell migration and provides a structural scaffold at cell adhesion that anchors the cell when the extracellular matrix proteins interact with...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...